Idorsia Ltd (LON: 0RQE)

Market Cap	136.33M
Revenue (ttm)	65.47M
Net Income (ttm)	-261.82M
Shares Out	n/a
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,657
Average Volume	110,507
Open	11.76
Previous Close	12.25
Day's Range	11.40 - 11.76
52-Week Range	2.87 - 17.80
Beta	1.29
RSI	45.88
Earnings Date	Feb 27, 2025

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQE

Financial Performance

In 2023, Idorsia's revenue was 152.39 million, an increase of 56.93% compared to the previous year's 97.10 million. Losses were -297.92 million, -64.01% less than in 2022.

Financial numbers in CHF